CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Design Therapeutics
DSGN
$355M
| $43.8K | ﹤0.01% |
11,357
-649
| -5% | -$2.51K |
|
|
ITOS
427
DELISTED
iTeos Therapeutics
ITOS
| $43.7K | ﹤0.01% |
7,328
-419
| -5% | -$2.5K |
|
428
Annexon
ANNX
$238M
| $41.3K | ﹤0.01% |
21,381
-1,221
| -5% | -$2.36K |
|
429
Corvus Pharmaceuticals
CRVS
$442M
| $41K | ﹤0.01% |
12,889
-736
| -5% | -$2.34K |
|
430
Foghorn Therapeutics
FHTX
$319M
| $40.7K | ﹤0.01% |
11,155
-633
| -5% | -$2.31K |
|
431
Inhibrx
INBX
$399M
| $40.6K | ﹤0.01% |
2,904
-165
| -5% | -$2.31K |
|
432
Y-mAbs Therapeutics
YMAB
$389M
| $39.8K | ﹤0.01% |
8,984
-513
| -5% | -$2.27K |
|
433
Tevogen Bio Holdings
TVGN
$173M
| $37.9K | ﹤0.01% |
35,112
-2,005
| -5% | -$2.17K |
|
|
CRGX
434
DELISTED
CARGO Therapeutics
CRGX
| $37.6K | ﹤0.01% |
9,232
-528
| -5% | -$2.15K |
|
435
AC Immune
ACIU
$227M
| $37.1K | ﹤0.01% |
19,837
-1,133
| -5% | -$2.12K |
|
436
Voyager Therapeutics
VYGR
$234M
| $37K | ﹤0.01% |
10,957
-626
| -5% | -$2.12K |
|
437
Listed Funds Trust Roundhill Magnificent Seven ETF
MAGS
$2.71B
| $36.7K | ﹤0.01% |
800
-2,401
| -75% | -$110K |
|
|
AMRN
438
Amarin Corp
AMRN
$314M
| $36K | ﹤0.01% |
4,016
-227
| -5% | -$2.03K |
|
|
CMPS
439
Compass Pathways
CMPS
$480M
| $35.6K | ﹤0.01% |
12,455
+1,673
| +16% | +$4.79K |
|
440
Neurogene
NGNE
$286M
| $34.9K | ﹤0.01% |
2,980
-170
| -5% | -$1.99K |
|
441
Lexicon Pharmaceuticals
LXRX
$396M
| $33.4K | ﹤0.01% |
72,509
-4,141
| -5% | -$1.91K |
|
442
Neumora Therapeutics
NMRA
$267M
| $32.4K | ﹤0.01% |
32,406
-1,851
| -5% | -$1.85K |
|
443
Lyell Immunopharma
LYEL
$231M
| $31.5K | ﹤0.01% |
2,930
-30
| -1% | -$323 |
|
|
THRD
444
DELISTED
Third Harmonic Bio
THRD
| $31.4K | ﹤0.01% |
9,038
-516
| -5% | -$1.79K |
|
445
Wolfspeed
WOLF
$196M
| $30.6K | ﹤0.01% |
10,000
| – | – |
|
446
4D Molecular Therapeutics
FDMT
$329M
| $30K | ﹤0.01% |
9,287
-515
| -5% | -$1.66K |
|
447
Tango Therapeutics
TNGX
$813M
| $29.7K | ﹤0.01% |
21,685
-1,092
| -5% | -$1.5K |
|
448
Larimar Therapeutics
LRMR
$347M
| $27.5K | ﹤0.01% |
12,799
-730
| -5% | -$1.57K |
|
|
SLN
449
Silence Therapeutics
SLN
$261M
| $26.6K | ﹤0.01% |
9,432
-531
| -5% | -$1.5K |
|
450
scPharmaceuticals
SCPH
$299M
| $26.4K | ﹤0.01% |
10,037
-573
| -5% | -$1.51K |
|